Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism
ConditionPulmonary Embolism (PE)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorRenJi Hospital
About this trial
The registry is to evaluate the safety and feasibility of catheter-directed aspiration for patients with high-risk and intermediate-high-risk pulmonary embolism using Acostream.
Eligibility criteria
Qualifiers
18≤Age≤85
Clinical symptoms and presentation consistent with pulmonary embolism (PE).
PE symptoms duration ≤ 14 days.
High risk PE patients with absolute contraindications to systemic thrombolysis or its failure (refractory circulatory collapse) not eligible for surgical embolectomy.
Disqualifiers
Pregnancy.
Refusal to sign the informed consent form.
Presence of intracardiac thrombus.
Presence of chronic left heart failure with an ejection fraction lower than 30% Diagnosed thrombophilia.
Trial design
Treatments tested in this trial
- Acostream aspiration
Treatment groups
127 Participants
are divided into 1 treatment groupSponsors and collaborators
RenJi Hospital
Lead sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Collaborator
Nantong University Affiliated Hospital
Collaborator
Chengdu University of Traditional Chinese Medicine
Collaborator
Shanghai No.1 Hospital
Collaborator
First Affiliated Hospital of Fujian Medical University
Collaborator
Jinhua Central Hospital
Collaborator
Source ClinicalTrials.gov